Loading...
Genprex, Inc.
GNPX•NASDAQ
HealthcareBiotechnology
$0.22
$-0.06(-20.89%)
Genprex, Inc. (GNPX) Stock Overview
Explore Genprex, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-1.25
↓ 69206.42%
EPS Growth
$-1.25
↓ 23545.13%
Operating Margin
-153060.21%
↑ 31.86%
ROE
-664.67%
↓ 69206.42%
Dividend Yield
0.00%
Analyst Recommendations data is not available for GNPXAnalyst Recommendations details for GNPX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
CEO
Mr. Ryan M. Confer M.S.
Employees
15
Headquarters
3300 Bee Cave Road, Austin, TX
Founded
2018